ライフサイエンスコーパス: human platelet

1 ), we developed a computational model of the human platelet.

2 RE syntaxin 8 (STX8) (Qc SNARE) in mouse and human platelets.

3 plays a role in binding and phagocytosis of human platelets.

4 ns of apolipoproteins in HDL and proteins in human platelets.

5 with a putative role in granule ontogeny in human platelets.

6 n, and proteolytic processing of proteins in human platelets.

7 augmented TRAP-induced TGF-beta1 release in human platelets.

8 of BCL-2-dependent tumors in vivo and spares human platelets.

9 phorylation was also potentiated with GFX in human platelets.

10 ovel pathway of Syk regulation by PKCbeta in human platelets.

11 fine the effects of PGN on the activation of human platelets.

12 m responsible for Syk negative regulation in human platelets.

13 the investigation of signal transduction in human platelets.

14 ubjects, we studied the function of PEAR1 in human platelets.

15 ced the collagen-induced STAT3 activation in human platelets.

16 e humanized mice had extremely low levels of human platelets.

17 ffects of anthrax lethal and edema toxins on human platelets.

18 s required for effective receptor traffic in human platelets.

19 tion of the protease-activated receptor 1 on human platelets.

20 associates with SHP-2, as well as SHP-1, in human platelets.

21 ect binding and entry of anthrax toxins into human platelets.

22 and vesicle-associated membrane protein-8 in human platelets.

23 e polymers of the size secreted by activated human platelets.

24 ined in VWF(R1326H) mutant mice infused with human platelets.

25 inhibition assays with fluorescently labeled human platelets.

26 Kv1.3 (KCNA3) is substantially expressed in human platelets.

27 ADP, resembling those in clopidogrel-treated human platelets.

28 resembling those in PAR1 antagonist-treated human platelets.

29 characterizing the ADP signaling pathways in human platelets.

30 integrin in Chinese hamster ovary cells and human platelets.

31 for talin regulation of integrin activity in human platelets.

32 ons under diverse experimental conditions in human platelets.

33 ructural properties and ability to stimulate human platelets.

34 icoid receptor have all been found active in human platelets.

35 at murine VWF-A1 supports limited binding of human platelets.

36 dissect lipid-signaling pathways such as in human platelets.

37 ing in complement activation on M1-activated human platelets.

38 n a PI3K-dependent manner upon activation of human platelets.

39 , as well as ex vivo activation of mouse and human platelets.

40 diverse functional proteins associated with human platelets.

41 lly regulated platelet aggregation in washed human platelets.

42 n and functional relevance of MS channels in human platelets.

43 nomotors cloaked with the plasma membrane of human platelets.

44 myocytes and the open canalicular system of human platelets.

45 for their xenogeneic hepatic consumption of human platelets.

46 PACSIN2 associated with FlnA in human platelets.

47 sed on the plasma membrane of both mouse and human platelets.

48 eticulocyte 15-lipoxygenase-1 (15-hLO-1) and human platelet 12-lipoxygenase (12-hLO) have been implic

49 Here we show that circRNAs are enriched in human platelets 17- to 188-fold relative to nucleated ti

50 To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUS

51 G), an extracellular matrix preparation from human platelets able to support the proliferation of end

52 osphate (of the size secreted from activated human platelets) accelerates factor V activation, comple

53 ontact with an allosteric inhibitor impaired human platelet accrual in damaged arterioles.

54 Here we demonstrate that human platelets activated with thrombin preferentially r

55 om DENV-activated human MCs led to increased human platelet activation.

56 nium salt (2MeSAMP) and ARC69931MX), inhibit human platelet activation.

57 maging and electron microscopy, we show that human platelets adherent to collagen are transformed int

58 al forms of human properdin bind directly to human platelets after activation by strong agonists in t

59 ed time-resolved phosphorylation patterns in human platelets after treatment with iloprost, a stable

60 Maternal alloantibodies against the human platelet Ag (HPA)-1a allotype of the platelet beta

61 Human platelet Ag (HPA)-1a, located on integrin beta3, i

62 roscopy we visualised membrane ballooning in human platelet aggregates adherent to collagen-coated su

63 9%), was associated with higher PAR4-induced human platelet aggregation and Ca2+ flux, and generated

64 Both agents inhibit human platelet aggregation but preserve clot retraction.

65 Thrombin initiates human platelet aggregation by coordinately activating pr

66 15 R-PGD(2) inhibited human platelet aggregation induced by the thromboxane re

67 10k inhibited serotonin-amplified human platelet aggregation with an IC(50) = 8.7 nM and h

68 n- and C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the eff

69 and functional activities as an inhibitor of human platelet aggregation.

70 5-HT release and SERT activity in efficient human platelet aggregation.

71 g site moderately decreased thrombin-induced human platelet aggregation.

72 In both rabbits and humans, platelet aggregation and activation were signifi

73 In human platelets, aldose reductase synergistically modula

74 Human platelet alloantigens (HPAs) reside on functionall

75 escribed the detection of antibodies against human platelet alloantigens by using gene-edited stem ce

76 We show that Cbl-b is expressed in human platelets along with c-Cbl, but in contrast to c-C

77 We show that human platelets also express high levels of inhibitory S

78 Similar to recombinant CXCL4, releasate from human platelets also reduced CD163 expression.

79 s and for the receptor expressed normally in human platelets an agonist-selective engagement of G(q)

80 published data for two cellular systems-the human platelet and erythrocyte under cold storage for us

81 sitol 3,4,5-trisphosphate-binding protein in human platelets and a key regulator of integrin alphaIIb

82 Using isolated human platelets and a mouse model of myocardial infarcti

83 elet-membrane-cloaked nanomotors disguise as human platelets and display efficient propulsion in bloo

84 also evaluated E. faecalis interactions with human platelets and found that growth of E. faecalis in

85 ated a superadditive Ca(2+) increase in both human platelets and human embryonic kidney 293 (HEK293)

86 Here, we used human platelets and human erythroleukemia (HEL) cells, w

87 he effect of shear stress on Ca(2+) entry in human platelets and Meg-01 megakaryocytic cells loaded w

88 Thus, viral infections upregulate IFITM3 in human platelets and MKs, and IFITM3 expression is associ

89 mune effector gene not previously studied in human platelets and MKs.

90 obes to map integrin receptor forces in live human platelets and mouse embryonic fibroblasts.

91 an dermal microvascular endothelial cells 1, human platelets and neutrophils, and C57BL/6NCrl mice.

92 hibition of alpha2beta1-mediated adhesion of human platelets and other cells to collagen.

93 ed human blood were used to study binding of human platelets and platelet-white blood cell aggregatio

94 uced aggregation and calcium mobilization in human platelets and reduce 12-HETE in beta-cells.

95 t ATX is stored in alpha-granules of resting human platelets and released upon tumor cell-induced pla

96 e for PKC downstream of 12-LOX activation in human platelets and suggest 12-LOX as a possible target

97 stem cells to introduce FVIII expression in human platelets and that human platelet-derived FVIII ca

98 rin alphaIIbbeta3, enhances SERT activity in human platelets and that integrin alphaIIbbeta3 interact

99 us serum significantly enhanced adherence to human platelets and that sortase deletion mutants (the D

100 Our results show that LXR-beta is present in human platelets and the LXR ligands, GW3965 and T0901317

101 To understand the mechanism, we isolate human platelets and treat them with influenza A virus.

102 , we validate extracellular flux analysis in human platelets and use this technique to screen for mit

103 ppraisal of protein networks and pathways in human platelets, and indicate the feasibility of differe

104 ptor 1, the primary receptor for thrombin on human platelets, and reduces recurrent thrombotic events

105 elet transfusions without evidence of HLA or human platelet antigen (HPA) antibodies.

106 aused by maternal alloantibodies against the human platelet antigen (HPA)-1a, which opsonizes fetal p

107 al antigenic difference; Leu33 generates the human platelet antigen 1a (HPA-1a), whereas Pro33 genera

108 Detection of alloantibodies to human platelet antigen 3 (HPA-3) and HPA-9 is especially

109 Incompatibility of the human platelet antigen-1 (HPA-1) system is the most comm

110 ernal generation of antibodies against fetal human platelet antigen-1a (HPA-1a), can result in intrac

111 sera with respect to alloantibodies against human platelet antigens (HPA).

112 ulin G (IgG) formed during pregnancy against human platelet antigens (HPAs) of the fetus mediates fet

113 patibility Complex of different species; IPD-human platelet antigens, alloantigens expressed only on

114 bed functional disparities between mouse and human platelets are reflected in differences at the tran

115 operties of 5G6 Fab fragment to GPIbalpha on human platelets as those to KL10 suggests that such an i

116 hysically proximal to talin and kindlin-3 in human platelets, as assessed biochemically, and by immun

117 Human platelets at a physiologic ratio of 1 platelet to

118 blocking antibodies resulted in reduction of human platelet binding and phagocytosis.

119 GTA1, CMAH LSECs exhibited reduced levels of human platelet binding in vitro when compared with GGTA1

120 18 expression by siRNA resulted in decreased human platelet binding.

121 mbopoiesis, we have developed a microfluidic human platelet bioreactor that recapitulates bone marrow

122 ted this dephosphorylation on Tyr-525/526 in human platelets but not in wild type murine platelets.

123 e not involved in the activation of purified human platelets by pneumococci.

124 l also reduces the xenogeneic consumption of human platelets by the porcine liver.

125 ere inhibited in TLR2-deficient mice and, in human platelets, by pretreatment with TLR2-blocking anti

126 sence of dual phosphorylated G6B-b in washed human platelets can reduce the EC(50) for both CRP and c

127 eived 2bF8LV-transduced hCB cells as long as human platelet chimerism persisted.

128 haIIbbeta3 and P2Y(1)(2) inhibitors to limit human platelet clot formation at doses recommended by th

129 Human platelets cocultured with HT29 cells rapidly adher

130 fibrinogen was augmented by niacin in washed human platelets, coincident with increased thromboxane (

131 Human platelets contain microRNAs (miRNAs) and miRNA pro

132 We also showed that human platelets contain the enzyme hyaluronidase-2 (HYAL

133 The direct binding of bacteria to human platelets contributes to the pathogenesis of infec

134 or migration, but negatively correlates with human platelet count and inhibits MK PP formation (PPF).

135 rug target retaining potential for enhancing human platelet counts.

136 he defective hemostatic function of mouse or human platelets deficient in cPLA(2)alpha.

137 We have recently reported that human platelets degrade HA from the surfaces of activate

138 In this study, we show that human platelets degrade the proinflammatory matrix HA th

139 FVIII expression in human platelets and that human platelet-derived FVIII can improve hemostasis in h

140 membrane (CM) with xenograft and recombinant human platelet-derived growth factor (rhPDGF) in guided

141 Recombinant human platelet-derived growth factor (rhPDGF) is safe an

142 al matrix (ADM) with and without recombinant human platelet-derived growth factor (rhPDGF).

143 d defect with the application of recombinant human platelet-derived growth factor (rhPDGF-BB) combine

144 Human platelet-derived growth factor B (hPDGFB) has been

145 tein human alpha-thrombin and an oncoprotein human platelet-derived growth factor B-chain (PDGF-BB) u

146 neralized bone allograft (FDBA), recombinant human platelet-derived growth factor mixture with a tita

147 lution structure of PDGFRbeta [a full-length human platelet-derived growth factor receptor], in compl

148 is systematic review, the use of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) led

149 phosphate (beta-TCP) + 0.3 mg/ml recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with

150 amel matrix derivative (EMD) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with

151 uine origin (eHAC), infused with recombinant human platelet-derived growth factor-BB (rhPDGF-BB), to

152 tissue graft (CTG) (control) or recombinant human platelet-derived growth factor-BB + beta-tricalciu

153 cs (enamel matrix derivative and recombinant human platelet-derived growth factor-BB plus beta-trical

154 Initial studies revealed that human platelets did not efficiently transmigrate across

155 rast to the murine study, galactosylation of human platelets did not prevent the accelerated platelet

156 Human platelets display a unique dual receptor system fo

157 tion or in blood plasma, and could aggregate human platelets, either isolated or in whole blood.

158 However, we observe that anucleate human platelets, either maintained in suspension culture

159 We found that this prodrug binds tightly to human platelets even after gel filtration, has a prolong

160 onment allowing us to manufacture functional human platelets ex vivo.

161 Human platelets express 2 thrombin receptors: protease-a

162 We found that human platelets express 284 miRNAs.

163 se data provide the first demonstration that human platelets express functional TLR2 capable of recog

164 Human platelets express RXRalpha and RXRbeta.

165 In the present study, we demonstrate that human platelets express TLR2, TLR1, and TLR6.

166 Human platelets express two thrombin receptors, protease

167 FcgammaRIIa phosphorylation did not occur in human platelets expressing a truncated beta3 cytoplasmic

168 t thrombin, collagen, or ionophore-activated human platelets externalize two phosphatidylserines (PSs

169 to affinity purify potential regulators from human platelet extracts.

170 ated by antibodies against complexes between human platelet factor 4 (hPF4) and heparin.

171 screened a panel of HDPs and determined that human platelet factor 4 (hPF4) kills malaria parasites i

172 In human platelets, Fc receptor gamma-chain IIa (FcgammaRII

173 Human platelet FVIII expression was introduced by 2bF8LV

174 the feasibility for lentivirus (LV)-mediated human platelet gene therapy of hemophilia A.

175 by using lipidomics that thrombin-activated human platelets generate a new type of eicosanoid that b

176 Recent studies show that human platelets have high levels of miR-30c and synthesi

177 In human platelet, higher sensitivity of PDE5 for sildenafi

178 c analysis of dematin-associated proteins in human platelets identified inositol 1,4,5-trisphosphate

179 In mice expressing both hPF4+ and human platelet IgG Fc receptor IIA (FcgammaRIIA), infusi

180 inhibited collagen-stimulated activation of human platelets in a dose-dependent manner but displayed

181 collagen-adhered, thrombin-activated, washed human platelets in a flow chamber.

182 Rapid increase in human platelets in blood to levels comparable with those

183 AS to predict calcium signaling responses of human platelets in EDTA-treated plasma to six different

184 ristocetin-induced platelet agglutination of human platelets in plasma with no influence on platelet

185 of histones on the procoagulant potential of human platelets in platelet-rich plasma (PRP) and in pur

186 ibitory effect of ADP-induced aggregation of human platelets in platelet-rich plasma.

187 ifications have on xenogeneic consumption of human platelets in the absence of immune-mediated graft

188 s also have shown the ability to phagocytose human platelets in the absence of immune-mediated injury

189 ry glioblastoma cells induced aggregation of human platelets in vitro, which could be abrogated by an

190 serine protease not previously identified in human platelets, increases with aging ( approximately 9-

191 Patient sera incubated with washed human platelets induced more C3 and C9 deposition on the

192 The binding of bacteria to human platelets is a likely central mechanism in the pat

193 Bacterial binding to human platelets is an important step in the pathogenesis

194 Even though GPCR signaling in human platelets is directly involved in hemostasis and t

195 Complement activation on human platelets is known to cause platelet degranulation

196 y expressed oxylipin-producing enzyme in the human platelet, is an essential component of FcgammaRIIa

197 GrmA is present and bioactive in human platelets, is higher in older adults, and controls

198 ures of the mammalian PFK1 tetramer, for the human platelet isoform (PFKP), in complex with ATP-Mg(2+

199 anules and releases functional FV(+)CD42b(+) human platelet-like particles in vitro and when infused

200 Proteomic analysis of human platelet LRRFIP1-interacting proteins indicated th

201 We describe the generation of human platelet lysate gel (hPLG), an extracellular matri

202 In human platelets, margatoxin reduced the P2X(1)- and thro

203 r 1 kg of body weight) significantly reduced human platelet-mediated thrombus formation in laser-inju

204 Human platelet membrane glycoprotein polymorphisms can b

205 gue infection that had significant levels of human platelets, monocytes/macrophages, and hepatocytes.

206 Desialylation of human platelet monolayers reduced adherence of SF100, wh

207 g of substrates (TAILS), to characterize the human platelet N-terminome, proteome, and posttranslatio

208 iously undescribed biosynthetic route during human platelet-neutrophil interactions for the proresolv

209 identified MK miR-125a-5p as associated with human platelet number but not leukocyte or hemoglobin le

210 Human platelet numbers decreased from 102 +/- 33 at begi

211 d approximately 80% of thrombus formation of human platelets on a collagen matrix.

212 y either pharmacologic inhibition of NOX2 in human platelets or genetic ablation of NOX2 in murine pl

213 Inhibition of Cx40 in human platelets or its deletion in mice reduces platelet

214 Pharmacological inhibition of PP2Ac in human platelets or PP2Acalpha knockdown in primary murin

215 erization, we have begun to characterize the human platelet palmitoylome.

216 PAR4, a low-affinity thrombin receptor in human platelets, participates in sustained platelet acti

217 In human platelets, PKC-theta-selective antagonistic (RACK;

218 Contact phase activation of human platelet-poor plasma by kaolin led to cleavage of

219 s, Bacillus cereus, initiated coagulation of human platelet-poor plasma only when confined.

220 E protein syntaxin-4 was strongly reduced in human platelets pretreated with PKC-theta RACK peptide,

221 ctional integrin alphaIIbbeta3 complexes and human platelets pretreated with the fibrinogen receptor

222 and Tymp(-/-) platelets, and in wild type or human platelets pretreated with TYMP inhibitor KIN59.

223 em for the study of pathologic mechanisms of human platelet production.

224 study demonstrates an extensive spectrum of human platelet protein phosphorylation in response to AD

225 ted the first comprehensive and quantitative human platelet proteome, comprising almost 4000 unique p

226 While human platelets rapidly kill Staphylococcus aureus, we f

227 In human platelets, recombinant PDI(ss-oo) inhibited aggreg

228 use macrophages are responsible for the poor human platelet reconstitution in humanized mice.

229 ss spectrometry analyses and immunoassays of human platelet releasates coupled with angiogenesis assa

230 In contrast, human platelets released by intrapulmonary-entrapped meg

231 se a cautionary note for the clinical use of human platelets released under standard ex vivo conditio

232 for the several-fold range in GPVI levels of human platelets remains to be determined.

233 Here we introduce a comprehensive human platelet repository (PlateletWeb) for systems biol

234 CE-mediated receptor shedding from mouse and human platelets requires p38 MAP kinase signaling.

235 CFTR loss of function in mouse or human platelets resulted in agonist-induced hyperactivat

236 Pharmacologic inhibition of 12-LOX in human platelets resulted in significant attenuation of F

237 sed traction forces in mouse fibroblasts and human platelets, revealing alignment between the organiz

238 ion of platelet aggregation as measured in a human platelet rich plasma (PRP) assay.

239 n generation time (TGT) coagulation assay in human platelet rich plasma (PRP).

240 ar inhibition of platelet aggregation in the human platelet rich plasma assay with IC(5)(0) values be

241 In human platelet-rich plasma (PRP), RvE1 selectively block

242 d its antiplatelet activity both in vitro in human platelet-rich plasma and in vivo in mice.

243 Microarray analyses of human platelet RNA demonstrated the presence of SVIL iso

244 Compared with human platelets, rodent platelets are less responsive to

245 sue of Blood, Kapur et al show that maternal human platelet-specific antigen 1a (HPA 1a)-specific ant

246 ells, nor do I observe affinity increases in human platelets stimulated with thrombin.

247 rine stroke and that AnxA1 is able to act on human platelets, suppressing classic thrombin-induced in

248 e serotonin release from thrombin-stimulated human platelet suspensions was successfully measured, an

249 GGTA1 CMAH livers also consumed fewer human platelets than ASGR1 livers in a single-pass model

250 sion model, GGTA1 CMAH livers consumed fewer human platelets than GGTA1 and WT livers.

251 y longer time to the onset of aggregation of human platelets than that of the parent strain.

252 Further, we demonstrated in human platelets that ABCC4 inhibition, when coupled with

253 ptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothe

254 Using human platelets, the human embryonic kidney 293 (HEK293)

255 e "canaliculi" structures for secretion from human platelets, the secretory machinery in single-cell

256 e of circular RNAs (circRNAs) in circulating human platelets, thereby revealing yet another facet of

257 nt in CPS Sia was more efficiently killed by human platelets, thrombin-activated platelet releasate,

258 cade, drives fibrin deposition and activates human platelets through protease-activated receptor-1 (P

259 xenoantibodies and therefore allows infused human platelets to circulate, can be used to study drug-

260 Integrin alpha2beta1-mediated adhesion of human platelets to monomeric type I collagen or to the G

261 Ex vivo, there was less adhesion of human platelets to von Willebrand factor under high shea

262 Whether sepsis alters the human platelet transcriptome and translational landscape

263 Human platelet transformation into balloons is part of t

264 ed in PP1calpha(-/-) murine platelets and in human platelets treated with a small-molecule inhibitor

265 cPLA(2)alpha-deficient mouse platelets or in human platelets treated with pyrrophenone, a cPLA(2)alph

266 ge tandem MS, here we first demonstrate that human platelet-type 12-lipoxygenase (12-LOX) can directl

267 Perfusion models were used to measure human platelet uptake in livers from WT, ASGR1, GGTA1, a

268 To investigate this model, we interrogate human platelets using approaches that include the suppor

269 escent gold nanoparticles are delivered into human platelets via a rapid, pH-controlled mechanism usi

270 e, lysin mediates the binding of S. mitis to human platelets via its interaction with fibrinogen on t

271 s12041331 and expression of PEAR1 protein in human platelets was confirmed by Western blotting and EL

272 The expression of PXR in human platelets was confirmed using immunoprecipitation

273 Consistent with reports utilizing human platelets, we found significantly reduced bleeding

274 In human platelets, we show that maximally activated P2X1 r

275 (RNA-Seq) and ribosome profiling of primary human platelets, we show the platelet transcriptome enco

276 Because LPA(5) transcripts are abundant in human platelets, we tested its antagonists on platelet a

277 uced hCB cells, whereas 5 of 7 survived when human platelets were 0.3% to 2%.

278 Next, when human platelets were coincubated with RBCs and then deox

279 rescein diacetate succinimidyl ester-labeled human platelets were exposed to PAEC/PFAEC/PLSEC and ana

280 Human platelets were incubated with Aspergillus conidia

281 Millions of human platelets were produced and showed to be functiona

282 In support of this possibility, human platelets were rapidly rejected after infusion int

283 P2Y12 overexpressed in HEK293, CHO cells and human platelets were used and responsiveness to differen

284 PMPs, generated from purified human platelets, were isolated by ultracentrifugation an

285 particles enclosed in the plasma membrane of human platelets, which are a unique population of cellul

286 robes per nanoparticle to be internalized in human platelets, which are not susceptible to transfecti

287 V-1-infected patients (n = 23) and in washed human platelets, which are the main source of circulatin

288 The expression of FcgammaRIIA by human platelets, which is their unique receptor for immu

289 density lipoprotein (HDL) and interaction of human platelets with a specific oxPL, and demonstrated i

290 Activation of human platelets with adenosine diphosphate (ADP) stimula

291 Treatment of human platelets with cyclosporin A gave a similar phenot

292 Treatment of human platelets with GSK3 inhibitors renders them more s

293 est that primary pig KC bind and phagocytose human platelets with involvement of CD18.

294 as established to measure the association of human platelets with liver sinusoidal endothelial cells

295 rker for its activation, upon stimulation of human platelets with PAR agonists SFLLRN and AYPGKF or G

296 iate platelet clearance, we incubated normal human platelets with patient serum containing an alphaII

297 Moreover, treating activated human platelets with phospholipase D enhanced the rates

298 Stimulation of washed human platelets with protease-activated receptor agonist

299 ets, ex vivo treatment of wild-type mouse or human platelets with the Vps34-specific inhibitors, SAR4

300 w-derived macrophages and thrombin activated human platelets yields results in agreement with literat